Consensus NewAmsterdam Pharma Company N.V. Deutsche Boerse AG

Stocks

KH6

NL00150012L7

Biotechnology & Medical Research

Real-time Estimate Tradegate 11:12:39 21/09/2026 +03			5-day change	1st Jan Change
19.75 ^EUR	+5.17%		+8.40%	-26.99%

08-26	NewAmsterdam Pharma Presents Data From Obicetrapib Development Program At European Society Of Cardiology Congress 2026	CI
08-14	Newamsterdam Pharma Company N.V. Announces Executive Changes	CI

99139a7991cb9575f.EK3MuzQ6bocdkxYqT1E44STrN6dlRZ6sVyuYamAxf_s.fv2rg2x-K8Ml_yUbNzdVgx20Vd4WHarkBWTUEDpYPbxTgP70eE854yr1Uw~f758707f61ec27df89a7d15623ff11d7

Analysts' recommendations: NewAmsterdam Pharma Company N.V.

08-06	RBC Adjusts NewAmsterdam Pharma PT to $50 From $51, Maintains Outperform Speculative Risk Rating	MT
07-21	BMO Capital Initiates NewAmsterdam Pharma at Outperform With $58 Price Target	MT
06-30	NewAmsterdam Pharma's Obicetrapib Could Capture Market Share, RBC Capital Markets Says	MT
06-30	RBC Raises Price Target on NewAmsterdam Pharma to $51 From $47, Keeps Outperform, Speculative Risk	MT
03-19	Truist Initiates NewAmsterdam Pharma at Buy With $57 Price Target	MT
01-21	RBC Raises Price Target on NewAmsterdam Pharma to $47 From $44, Keeps Outperform, Speculative Risk	MT
11-06	RBC Raises Price Target on NewAmsterdam Pharma to $44 From $39, Keeps Outperform, Speculative Risk	MT
25/08/25	Wells Fargo Initiates Coverage on NewAmsterdam Pharma With Overweight Rating, $45 Price Target	MT
07/08/25	RBC Lifts Price Target on NewAmsterdam Pharma to $39 From $38, Keeps Outperform, Speculative Risk	MT
17/07/25	Goldman Sachs Initiates Coverage on NewAmsterdam Pharma With Neutral Rating, $27 Price Target	MT
17/06/25	Citigroup Initiates NewAmsterdam Pharma at Buy With $42 Price Target	MT
10/06/25	Stifel Nicolaus Initiates Coverage on NewAmsterdam Pharma With Buy Rating, $44 Price Target	MT
04/06/25	Cantor Fitzgerald Initiates NewAmsterdam Pharma Overweight With $42 Price Target	MT
30/12/24	HC Wainwright Initiates NewAmsterdam Pharma at Buy With $48 Price Target	MT
28/08/24	Needham Initiates NewAmsterdam Pharma at Buy With $36 Price Target	MT
15/05/24	TD Cowen Starts NewAmsterdam Pharma With Buy Rating	MT
14/03/24	Scotiabank Starts NewAmsterdam Pharma With Sector Outperform Rating, $35 Price Target	MT
29/02/24	RBC Raises Price Target on NewAmsterdam Pharma to $31 From $25, Keeps Outperform, Speculative Risk	MT
18/01/24	Guggenheim Starts NewAmsterdam Pharma With Buy Rating, $30 Price Target	MT
30/10/23	RBC Initiates NewAmsterdam Pharma at Outperform With Speculative Risk Qualifier, $25 Price Target	MT
03/04/23	Credit Suisse Lifts NewAmsterdam Pharma's Price Target to $22 From $21, Keeps Outperform Rating	MT
06/01/23	Credit Suisse Starts NewAmsterdam Pharma at Outperform With $21 Price Target	MT
20/12/22	SVB Securities Initiates Coverage on NewAmsterdam Pharma With Outperform Rating, $19 Price Target	MT
20/12/22	SVB Securities Starts NewAmsterdam Pharma at Outperform With $19 Price Target	MT
19/12/22	William Blair Starts NewAmsterdam Pharma at Outperform	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	WUXI APPTEC CO., LTD.					+16.92%
	ARGENX SE					+17.91%
	WUXI BIOLOGICS (CAYMAN) INC.					+15.47%
	INSMED INCORPORATED					+66.29%
	BIONTECH SE					+23.62%
	GENMAB A/S					+8.57%
	PHARMAESSENTIA CORPORATION					+15.96%
	EXELIXIS, INC.					-8.01%
	SUMMIT THERAPEUTICS INC.					+62.99%
	Average					+24.41%
	Weighted average by Cap.					+22.69%